Navigation Links
Implementing comparative effectiveness research: Lessons from the mammography screening controversy
Date:6/22/2010

(Garrison, NY) The firestorm that followed the November 2009 release of guidelines that would have reduced use of screening mammograms in women aged 40 to 49 highlights challenges for implementing the findings of comparative effectiveness research (CER), according to a new analysis. Meeting such challenges which may become more common due to increased funding for CER requires better communication to the public and stakeholders about evidence and its connection to health care quality and efficiency.

Michael K. Gusmano, a research scholar at The Hastings Center, and Bradford H. Gray, a senior fellow at the Urban Institute, write in Academy Health Reports that while "the idea of using evidence to improve health care policy decisions enjoys [broad] support," its implementation "can encounter great resistance," especially if it suggests that widely promoted technologies may not be worth the cost.

The authors cite the recent powerful objections to mammography screening recommendations released by the U.S. Preventive Services Task Force (USPSTF) that would reduce would eliminate the use of routine breast cancer screening mammograms in most women ages 40 to 49. These recommendations, based on a detailed review of research, concluded that the harms of the screening outweighed its benefits in this group.

While some groups, such as Breast Cancer Action, the National Women's Health Network, and the National Breast Cancer Coalition, supported the recommendations, their voices were drowned by "an avalanche of negative reactions from professional associations (including the American Cancer Society), patient advocates, and elected officials from both political parties," as well as Health and Human Services Secretary Kathleen Sebelius. Ultimately, the U.S. Senate agreed to an amendment that amounted to requiring the federal government to ignore the 2009 USPSTF recommendations in the newly enacted health reform legislation, and revert to the 2002 recommendations.

Examining the reasons behind the controversy, and what it portends for CER, the authors cite communications troubles in the way that the recommendations which took constituents by surprise were developed and released into a "highly charged political environment," amidst broader societal concerns about government control of health care. They note that CER is "most likely to face challenges when findings call for some degree of `disinvestment' reducing use of an established technology," as did the mammogram guidelines.

"Establishing broader support for the value of health services research, coupled with sustained efforts to communicate more effectively with the public, is crucial as the United States grapples with how best to improve the quality and efficiency of its health system," Gusmano and Gray conclude.


'/>"/>

Contact: Michael Turton
845-424-4040 x242
The Hastings Center
Source:Eurekalert

Related medicine news :

1. New Harris Corporation Program Assists Healthcare Organizations in Implementing CONNECT Solution for NHIN Connectivity
2. Developing a cyberinfrastructure for comparative effectiveness in cancer research
3. Lawrence Berkeley National Laboratory and OpenHelixTM Announce an Updated Free Tutorial Suite for VISTA: Tools for Comparative Genomics
4. SNM receives grant from AHRQ for comparative effectiveness research
5. Comparative-effectiveness study confirms new treatment for diabetic macular edema
6. Journal editors call for standards in comparative effectiveness research
7. New study shows effectiveness of MEND program in prevention and treatment of pediatric obesity
8. APS Healthcare Issues First Award to South Carolina Providers Using Data to Increase Effectiveness of Mental Health Treatment
9. Review Questions Tamiflus Effectiveness
10. GAINs Effectiveness in Reducing Malnutrition Confirmed in its New Annual Report
11. Report suggests similar effectiveness among options for managing low-risk prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their media ... Pro X," said Christina Austin - CEO of Pixel Film Studios. , ProSlice ... X users can now reveal the media of their split screens with growing ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... First ... United States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell ... facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: